Therapie der chronischen Prurigo: Update und Perspektive

Despite the high burden in patients with chronic prurigo (CPG), the first and so far only approved systemic therapy for this disease, dupilumab, has only been available since 2022. Therefore, treatment is mostly based on expert recommendations for off-label therapies. We aim to provide an overview of current therapies and possible future therapeutic drugs for CPG patients, which are currently in clinical trials.

For this review, a systematic literature and clinical trial search was conducted via PubMed and Clinical Trials using the terms “chronic prurigo”, “chronic nodular prurigo”, “prurigo nodularis” and “therapy”.

Multiple new therapeutic agents are currently under investigation in clinical trials, providing promising results for future treatment options. Moreover, an annotated checklist was developed recently to improve therapeutic decision-making in daily clinical practice with CPG patients.